| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/BIOSTATISTICS/1.3.231 |
| P698 | PubMed publication ID | 12933506 |
| P5875 | ResearchGate publication ID | 2630688 |
| P894 | zbMATH Open document ID | 1072.62657 |
| P50 | author | Hans C. van Houwelingen | Q59660364 |
| P2093 | author name string | Gail MH | |
| Pfeiffer R | |||
| Carroll RJ | |||
| P433 | issue | 3 | |
| P921 | main subject | meta-analysis | Q815382 |
| P6104 | maintained by WikiProject | WikiProject Mathematics | Q8487137 |
| P304 | page(s) | 231-246 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Biostatistics | Q4915301 |
| P1476 | title | On meta-analytic assessment of surrogate outcomes | |
| P478 | volume | 1 |
| Q38803203 | A Bayesian hierarchical surrogate outcome model for multiple sclerosis |
| Q35016789 | A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables |
| Q24803339 | A perfect correlate does not a surrogate make |
| Q37553617 | A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials |
| Q36740970 | A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials |
| Q51875233 | Alternative methods to evaluate trial level surrogacy. |
| Q38763752 | An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest |
| Q38069494 | Are arterial grafts superior to vein grafts for revascularisation of the right coronary system? A systematic review |
| Q64055679 | Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy |
| Q36381197 | Bayesian methods for evidence synthesis in cost-effectiveness analysis |
| Q38418590 | Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization |
| Q33269179 | Bivariate random-effects meta-analysis and the estimation of between-study correlation |
| Q35167912 | Clinical biomarkers in drug discovery and development |
| Q39869593 | Comparing biomarkers as trial level general surrogates |
| Q37101600 | Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective |
| Q34386133 | Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop |
| Q33805412 | Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis |
| Q37107029 | Evaluating a surrogate endpoint at three levels, with application to vaccine development |
| Q78726678 | Evaluating surrogate endpoints |
| Q35672166 | Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes |
| Q40268629 | Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints |
| Q42909774 | Hard, harder, hardest: principal stratification, statistical identifiability, and the inherent difficulty of finding surrogate endpoints |
| Q92995674 | How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials |
| Q37016467 | Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints |
| Q40623665 | Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology |
| Q41215381 | Links between analysis of surrogate endpoints and endogeneity |
| Q43787549 | Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling |
| Q37458317 | Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. |
| Q34015951 | Modelling the effect of baseline risk in meta-analysis: a review from the perspective of errors-in-variables regression. |
| Q40028428 | Multiparameter evidence synthesis in epidemiology and medical decision-making |
| Q30976009 | Multivariate meta-analysis using individual participant data. |
| Q40336922 | Multivariate meta-analysis with an increasing number of parameters |
| Q33804037 | Multivariate meta-analysis: potential and promise |
| Q37362990 | On assessing surrogacy in a single trial setting using a semicompeting risks paradigm |
| Q45029688 | On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints |
| Q57286668 | Optimizing and evaluating biomarker combinations as trial-level general surrogates |
| Q36303649 | Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials |
| Q45288765 | Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer |
| Q35556037 | Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time |
| Q33648196 | Predicting treatment effects using biomarker data in a meta‐analysis of clinical trials |
| Q34065063 | Principal stratification in causal inference |
| Q33800697 | Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer |
| Q33774900 | Radial artery versus saphenous vein conduits for coronary artery bypass surgery: forty years of competition--which conduit offers better patency? A systematic review and meta-analysis |
| Q92076419 | Shared parameter model for competing risks and different data summaries in meta-analysis: Implications for common and rare outcomes |
| Q35035407 | Statistical challenges in the evaluation of surrogate endpoints in randomized trials |
| Q38356102 | Statistical evaluation of surrogate endpoints with examples from cancer clinical trials |
| Q39906181 | Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials |
| Q36407392 | Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition. |
| Q36727471 | Surrogate endpoint analysis: an exercise in extrapolation |
| Q38829245 | Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques |
| Q30758427 | Surrogate markers and joint models for longitudinal and survival data |
| Q42858959 | Surrogate measures and consistent surrogates |
| Q36966415 | The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat |
| Q43544469 | The evaluation of multiple surrogate endpoints |
| Q40127940 | The intermediate endpoint effect in logistic and probit regression. |
| Q34570123 | The promise and peril of surrogate end points in cancer research |
| Q41484464 | Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints |
Search more.